During LUAD progression, cancer cells release various pro-angiogenic factors, including vascular endothelial growth factor (VEGF), which compensates for hypoxia by promoting neoangiogenesis or vasculature remodeling [37]. The gene discussed is VEGFA; the disease is cancer.